1.Risk analysis of perioperative outcomes of lung transplantation and the prediction of delayed extubation
Peigen GAO ; Lei ZHANG ; Xiaxian SHEN ; Pei ZHANG ; Chenyang DAI ; Yuping LI ; Wenxin HE ; Qiankun CHEN ; Gening JIANG ; Chang CHEN
Chinese Journal of Organ Transplantation 2023;44(11):645-652
Objective:To explore the risk factors of perioperative outcomes of lung transplantation and establish a predictive model for delayed extubation after lung transplantation.Methods:From January 1, 2020 to December 31, 2022, 104 lung transplantation recipients were retrospectively collected to identify the risk factors of early post-operative outcome.According to the timing of extubation post-lung transplantation, they were assigned into two groups of normal(77 cases)and delayed(27 cases). Baseline profiles, type of primary diagnosis, cold ischemic duration and lung transplantation approach were compared between two groups.The factors with significant difference were examined by univariate and multivariate Logistic regression.Furthermore, multivariate logistic model was visualized by a nomogram.Receiver operating characteristic(ROC)curve and decision curve analysis(DCA) were performed for evaluating the model's predictive performance and its value for clinical utilization.Results:The postoperative mortality rate was 9.6%.Delayed extubation was a strong predictor for postoperative mortality.Cold ischemic time outperformed others variates in terms of delayed extubation prediction.AUC of cold ischemic time and multivariate logistic model was 0.75(95% CI: 0.69-0.81)and 0.87(95% CI: 0.82-0.91). Conclusions:Delayed postoperative extubation is a key predictor of early post-lung transplantation mortality.The established predictive model may effectively identify high-risk patients for preventive intervention and survival improvement post-lung transplantation.
2.Guideline for postoperative rehabilitation treatment following vertebral augmentation for osteoporotic vertebral compression fracture (version 2022)
Zhengwei XU ; Dingjun HAO ; Liming CHENG ; Baorong HE ; Bohua CHEN ; Chen CHEN ; Fei CHE ; Jian CHEN ; Qixin CHEN ; Liangjie DU ; Shunwu FAN ; Zhong FANG ; Shiqing FENG ; Yanzheng GAO ; Haishan GUAN ; Zhong GUAN ; Hua JIANG ; Weimin JIANG ; Dianming JIANG ; Jun JIANG ; Yue JIANG ; Lijun HE ; Yuan HE ; Bo LI ; Tao LI ; Jianjun LI ; Xigong LI ; Yijian LIANG ; Bin LIN ; Bin LIU ; Bo LIU ; Yong LIU ; Zhibin LIU ; Xuhua LU ; Chao MA ; Lie QIAN ; Renfu QUAN ; Hongxun SANG ; Haibo SHEN ; Jun SHU ; Honghui SUN ; Tiansheng SUN ; Jun TAN ; Mingxing TANG ; Sheng TAO ; Honglin TENG ; Yun TIAN ; Jiwei TIAN ; Qiang WANG ; Xinwei WANG ; Jianhuang WU ; Peigen XIE ; Weihong XU ; Bin YAN ; Yong YANG ; Guoyong YIN ; Xiaobing YU ; Yuhong ZENG ; Guoqing ZHANG ; Xiaobo ZHANG ; Jie ZHAO ; Yue ZHU
Chinese Journal of Trauma 2022;38(11):961-972
Osteoporotic vertebral compression fracture (OVCF) can lead to lower back pain and may be even accompanied by scoliosis, neurological dysfunction and other complications, which will affect the daily activities and life quality of patients. Vertebral augmentation is an effective treatment method for OVCF, but it cannot correct unbalance of bone metabolism or improve the osteoporotic status, causing complications like lower back pain, limited spinal activities and vertebral refracture. The post-operative systematic and standardized rehabilitation treatments can improve curative effect and therapeutic efficacy of anti-osteoporosis, reduce risk of vertebral refracture, increase patient compliance and improve quality of life. Since there still lack relevant clinical treatment guidelines for postoperative rehabilitation treatments following vertebral augmentation for OVCF, the current treatments are varied with uneven therapeutic effect. In order to standardize the postoperative rehabilitation treatment, the Spine Trauma Group of the Orthopedic Branch of Chinese Medical Doctor Association organized relevant experts to refer to relevant literature and develop the "Guideline for postoperative rehabilitation treatment following vertebral augmentation for osteoporotic vertebral compression fracture (2022 version)" based on the clinical guidelines published by the American Academy of Orthopedic Surgeons (AAOS) as well as on the principles of scientificity, practicality and advancement. The guideline provided evidence-based recommendations on 10 important issues related to postoperative rehabilitation treatments of OVCF.
3.Twelve-week of sofosbuvir/velpatasvir therapeutic regimen for chronic hepatitis C patients in northwest region of China: a real-world multicenter clinical study
Qiang XU ; Wei ZHANG ; Yuxiu MA ; Caini HE ; Liting ZHANG ; Yilihamu ABULITIFU ; Yu LI ; Nan WANG ; Hongli WANG ; Yunyu ZHAO ; Xu GAO ; Peigen GAO ; Xingyang SU ; Shen LI ; Yuanyuan LIU ; Feng GUO ; Zhangqian CHEN ; Hailing LIU ; Xiaoqin GAO ; Jianjun FU ; Guoying YU ; Xiaozhong WANG ; Jiuping WANG ; Yongping ZHANG ; Fanpu JI
Chinese Journal of Hepatology 2021;29(11):1046-1052
Objective:To study the real-world outcome of China FDA-approved Sofosbuvir (SOF)/Velpatasvir (VEL) in Northwest China.Methods:In this multicenter, prospective, real-world cohort study, we recruited patients from 10 sites from Northwest China, who were chronically infected with HCV GTs 1-6 from 06/2018 to 09/2019. Patients received SOF (400mg)/VEL (100mg) for 12 weeks, and with ribavirin 900-1200 mg for GT3 cirrhosis and for any genotype decompensated cirrhosis. The primary endpoint was sustained virological response at 12-weeks post-treatment (SVR12) and safety. The secondary endpoint was the change of liver function after the achievement of SVR12.Results:Totally, 143 patients were enrolled in the study, four patients were lost to follow-up and one died during the follow-up, 138 patients were included in per-protocol analysis. Of the 138 patients, the mean age 53 years, 53.6% male, 94.2% Han nationality, 53.6% liver cirrhosis, 10.1% HBsAg +, 6.5% renal dysfunction, 5.1% treatment-experienced, and 16.7% patients received ribavirin treatment. The genotype distribution was as follows: 35.5% GT1, 42.8% GT2, 15.9% GT3, and 5.8% un-typed. The SVR12 rate was 96.5% (138/143, 95% CI: 93.5%-99.6%) for intention-to-treat analysis, and in per-protocol analysis, all 138 patients obtained SVR12 (100%). Compared with baseline, the serum total bilirubin, ALT and AFP levels decreased (all P < 0.05), as well as increased ALB and platelet count (all P < 0.001) at post-treatment 12-weeks. Overall adverse events (AEs) rate is 29.0%, and the most common AEs were anemia (14.5%) and fatigue (8.0%). Severe side effects (edema and fatigue) occurred in 2 patients, one of whom needed a short-term interruption of treatment due to fatigue. Conclusion:In this real-world cohort study, 12-week SOF/VEL regimen with or without ribavirin achieved high SVR12 rates (96.5%-100% overall) with excellent safety profile among patients with HCV GT1/2/3 infection including patients with GT3 and cirrhosis, and led to improvement of liver function.
4.Investigation of free amino acid, total phenolics, antioxidant activity and purine alkaloids to assess the health properties of non-Camellia tea.
Wu BI ; Chunnian HE ; Yunyun MA ; Jie SHEN ; Linghua Harris ZHANG ; Yong PENG ; Peigen XIAO ;
Acta Pharmaceutica Sinica B 2016;6(2):170-181
To find novel functional beverages from folk teas, 33 species of frequently used non-Camellia tea (plants other than Camellia) were collected and compared with Camellia tea (green tea, pu-erh tea and black tea) for the first time. Data are reported here on the quantities of 20 free amino acids (FAAs) and three purine alkaloids (measured by UHPLC), total polyphenols (measured by Folin-Ciocalteu assay), and antioxidant activity (DPPH). The total amounts of FAAs in non-Camellia tea (0.62-18.99 mg/g) are generally less than that of Camellia tea (16.55-24.99 mg/g). However, for certain FAAs, the quantities were much higher in some non-Camellia teas, such as γ-aminobutyric acid in teas from Ampelopsis grossedentata, Isodon serra and Hibiscus sabdariffa. Interestingly, theanine was detected in tea from Potentilla fruticosa (1.16±0.81 mg/g). Furthermore, the content of polyphenols in teas from A. grossedentata, Acer tataricum subsp. ginnala are significantly higher than those from Camellia tea; teas from I. serra, Pistacia chinensis and A. tataricum subsp. ginnala have remarkable antioxidant activities similar to the activities from green tea (44.23 μg/mL). Purine alkaloids (caffeine, theobromine and theophylline) were not detected in non-Camellia teas. The investigation suggest some non-Camellia teas may be great functional natural products with potential for prevention of chronic diseases and aging, by providing with abundant polyphenols, antioxidants and specific FAAs.
5.Determination of hesperidine inErchen mixture by HPLC
Jing LIU ; Peigen HE ; Zhihao LI ; Peng LI
International Journal of Traditional Chinese Medicine 2014;(10):909-911
Objective To establish a method for the determination of hesperidine inErchen mixture. Methods HPLC method was used with Fortis C18(250 mm×4.6 mm,5μm)column and the mobile phase consisted of acetonitrile-acetic acid-water(22∶4∶74). The flow rate was 1.0 ml/min,the column temperature was 30℃, and the UV detector was set at 283 nm.Results The linear ranges of hesperidine was 2.86-57.20μg(r=0.999 8). The average recovery of Aloin was 99.4%.Conclusion The method is rapid, reliable, simple, repeatable and with high specificity. It can be an important supplement for Erchen mixture elevated standard.
6.Chemical constituents of Kadsura oblongifolia and evaluation of their toxicity.
Jin ZHANG ; Zhiming WANG ; Kechun LIU ; Qiuxia HE ; Yaodong QI ; Bengang ZHANG ; Haitao LIU ; Peigen XIAO
Acta Pharmaceutica Sinica 2014;49(9):1296-303
To study the chemical constituents of K. oblongifolia, silica gel column chromatography, MCI and Sephadex LH-20 were used to separate the 70% acetone extract of the stems of K. oblongifolia. The structures of the isolated compounds have been established on the basis of physicochemical and NMR spectroscopic evidence as well as ESI-MS in some cases. Twenty compounds were obtained and identified as heteroclitalignan A (1), kadsulignan F (2), kadoblongifolin C (3), schizanrin F (4), heteroclitalignan C (5), kadsurarin (6), kadsulignan O (7), eburicol (8), meso-dihydroguaiaretic acid (9), kadsufolin A (10), tiegusanin M (11), heteroclitin B (12), (7'S)-parabenzlactone (13), angeloylbinankadsurin B (14), propinquain H (15), quercetin (16), kadsulignan P (17), schizanrin G (18), micrandilactone C (19) and (-)-shikimic acid (20). Compouds 1, 5, 8, 11-15, 18 and 20 were isolated from this plant for the first time. Toxicity of compounds 1-10 were evaluated with zebrafish model to observe the effect on its embryonic development and heart function. The results showed that compounds 7, 9 and 10 caused edema of zebrafish embryo and decreased the heart rate of zebrafish, which exhibited interference effect on heart development of zebrafish.
7.Pharmaphylogeny vs. pharmacophylogenomics: molecular phylogeny, evolution and drug discovery.
Dacheng HAO ; Peigen XIAO ; Ming LIU ; Yong PENG ; Chunnian HE
Acta Pharmaceutica Sinica 2014;49(10):1387-94
With the surge of high-throughput sequencing technology, it is becoming popular to perform the phylogenetic study based on genomic data. A bundle of new terms is emerging, such as phylogenomics, pharmacophylogenomics and phylotranscriptomics, which are somewhat overlapping with pharmaphylogeny. Phylogenomics is the crossing of evolutionary biology and genomics, in which genome data are utilized for evolutionary reconstructions. Pharmaphylogeny, advocated by Prof. Pei-gen Xiao since 1980s, focuses on the phylogenetic relationship of medicinal plants and is thus nurtured by molecular phylogeny, chemotaxonomy and bioactivity studies. Phylogenomics can be integrated into the flow chart of drug discovery and development, and extend the field of pharmaphylogeny at the omic level, thus the concept of pharmacophylogenomics could be redefined. This review gives a brief analysis of the association and the distinguished feature of the pharmaphylogeny related terms, in the context of plant-based drug discovery and sustainable utilization of pharmaceutical resource.
8.Comparative Studies on Antioxidant Activities of Green Tea and Four Tree-type Non-Camellia Teas
Wanying WANG ; Wei XIAO ; Lijia XU ; Yong PENG ; Chunnian HE ; Peigen XIAO
World Science and Technology-Modernization of Traditional Chinese Medicine 2013;(7):1526-1531
This article was aimed to compare the antioxidant activities of Green tea and four tree-type non-Camellia teas. The antioxidant activities of the water extract of Green tea, Eagle tea, Large-leaved Kuding tea, Shiya tea and Qingqianliu tea were evaluated with four different in vitro assays including 1,1-diphenyl-2-picryl-hydrazyl (DPPH), ferric-reducing antioxidant power (FRAP), ferrous ion-chelating (FIC) and β-carotene-linoleate bleaching assay. In addition, the polyphenol contents of different teas were estimated by the Folin-Ciocalteu assay. The results showed that Shiya tea had strong antioxidant activity; its FIC and FRAP abilities are better compared with Green tea. The Eagle tea and Large-leaved Kuding tea have better antioxidant activity. The FRAP activity of Large-leaved Kuding tea was better than green tea. The DPPH of Eagle tea and Large-leaved Kuding tea were slightly lower than Green tea, but higher than the butylated hydroxytoluene (BHT). The antioxidant ability of Qingqianliu tea was the lowest. It was concluded that Shiya tea, Eagle tea, Large-leaved Kuding tea had relatively high development value which re-quires in-depth research and promotion.
9.Quick determination of five sweet constituents in Duosuike Tiancha by RSLC.
Chunnian HE ; Yong PENG ; Wei XIAO ; Yuli HU ; Peigen XIAO
China Journal of Chinese Materia Medica 2012;37(7):961-965
Duosuike Tiancha contain multiple dihydrochalcone sweet constituents, which are mainly active constituents. For the purpose of overall assessment on quality Duosuike Tiancha, 5 sweet dihydrochalcones in Duosuike Tiancha, phloridzin, phloretin-4'-beta-D-glucopyranoside, 3'-O-acetylphloridzin, 2'-O-acetylphloridzin and phloretin are determined as indicators. The separation was carried out through a isocratic elution using a Waters Acquity UPLC BRH C18 (2.1 mm x 100 mm, 1.7 microm) column and a mobile phase consisting of water (75%) and acetonitrile (25%) at a flow rate of 0.5 mL x min(-1). The detection wavelength was set at 285 nm. The column temperature was 40 degrees C. Under the optimized conditions, all the 5 sweet constituents were successfully separated with in 6 min, and good linearity (r2 > 0.999 1) was achieved. The linear range (g x L(-)) and recoveries were tested with results of 0.022 2-0.444 (98.37%), 0.102 84. 112 (97.32%), 0.003 39-0.067 68 (96.77%), 0.005 1-0.204 (98.85%) and 0.000 538-0.010 76 (100.91%) respectively. The results indicate that the content of the 5 dihydrochalcones were 7.83-62.37, 114.24-272.35, 0-1.02, 0-5.11 and 0.10-1.19 mg x g(-1), respectively. Furthermore, with certain regularity between their content and the sample size, harvest time. The separation and analysis method are fast and simple, as evidenced by the fact that the gradient elution is adopted to rapidly determine one sample within six minutes. Therefore, it can be used for dsetermine 5 sweet dihydrochalcones Duosuike Tiancha.
Chalcones
;
chemistry
;
Chromatography, High Pressure Liquid
;
Drugs, Chinese Herbal
;
chemistry
;
Fagaceae
;
chemistry
10.Chemical constituents of Dolomiaea souliei.
Hu WEI ; Chunnian HE ; Yong PENG ; Guoxu MA ; Peigen XIAO
China Journal of Chinese Materia Medica 2012;37(9):1249-1253
OBJECTIVETo study the chemical constituents of Dolomiaea souliei.
METHODVarious chromatographic techniques were adopted to separate the constituents, and the spectrum analysis was made to identify their structures.
RESULTSeventeen compounds were isolated and identified as: dehydrocostus lactone (1), costunolide (2), mokko lactone (3), santamarine(4), reynosin (5), 4alpha-hydroxy-4beta-methyldihydrocostol (6), sulfocostunolide A (7), beta-costic acid (8), beta-cyclocostunolide (9), vladinol A (10), ursolic acid (11), betulinic acid (12), betulin (13), dibutyl terephthalate (14), dibutyl phthalate (15), uridine (16), and emodin (17).
CONCLUSIONCompounds 6-9 and 12-17 were obtained from this genus for the first time, and compound 11 was obtained from this plant for the first time.
4-Butyrolactone ; analogs & derivatives ; chemistry ; Asteraceae ; chemistry ; Emodin ; chemistry ; Lactones ; chemistry ; Sesquiterpenes ; chemistry ; Triterpenes ; chemistry


Result Analysis
Print
Save
E-mail